Skip to content
Peptidepedia

SS-31 (Elamipretide) Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Published clinical trials present a favorable safety profile, with most adverse events being mild and consistent with placebo rates for serious events.

Commonly Reported:

  • Injection site reactions including redness, mild swelling, and localized pain
  • Headache (reported at slightly higher rates than placebo in some trials)
  • Nausea (typically mild and transient)

Less Commonly Reported:

  • Dizziness
  • Fatigue (distinct from the underlying condition being treated)
  • Gastrointestinal discomfort (typically resolving without intervention)

Serious Adverse Events: No serious adverse events have been definitively attributed to SS-31 in published clinical trials. Theoretical concerns about downstream cellular signaling effects from broad mitochondrial optimization exist but have not materialized as clinical toxicity signals in trials to date. No carcinogenicity evidence has emerged in preclinical research.

Sourcing Risks: Individuals sourcing SS-31 from unregulated research chemical suppliers face contamination and purity risks that are separate from the compound's intrinsic safety profile. Quality and purity cannot be verified without independent third-party testing. The peptide purity testing guide explains how to evaluate supplier certificates of analysis.

Frequently Asked Questions

Clinical trials lasting up to 36 weeks have not revealed significant safety concerns. No serious adverse events have been definitively attributed to SS-31 in published trials. However, long-term safety data in healthy populations remains limited, and individuals sourcing SS-31 from unregulated research chemical suppliers face contamination risks.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
  2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  3. Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004230.
  4. Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
  5. Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17-28.
  6. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
  7. Stealth BioTherapeutics. Elamipretide Development Program.
  8. Sabbah HN, et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206.
  9. Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
←Read the full SS-31 (Elamipretide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”